Skip to main content

Advanced Search

Haematologica
  • Home
  • Current Issue
  • Ahead Of Print
  • Archive
  • Submit a Manuscript
    • Author Guidelines
    • Reviewer Guidelines
    • Submit a Manuscript
    • Track a Manuscript
  • About Us
    • About Haematologica
    • Editorial Board
    • Our Policies
  • More
    • Advertising
    • Rights & Permissions
    • Alerts
    • Feedback
    • Contact
Acute myeloid leukemia and follicular lymphoma after very low dose radioiodine therapy for thyroid diseases
Daniele Focosi, Sara Galimberti, Mario Petrini
Haematologica September 2007 92: e96-e97; doi:10.3324/haematol.11981
Daniele Focosi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: focosi@icgeb.org
Sara Galimberti
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mario Petrini
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site

Author Affiliations

  1. Daniele Focosi1⇓,
  2. Sara Galimberti1 and
  3. Mario Petrini1
  1. 1 Division of Hematology, Azienda Ospedaliera Universitaria Santa Chiara, Pisa, Italy
  1. #Corresponding author: focosi{at}icgeb.org
  • Article
  • Info & Metrics
  • PDF
Loading

Introduction

Radioiodine (131I) has been used in the treatment of thyroid cancer in order to eliminate residual thyroid tissue after thyroidectomy and to treat metastatic disease. Leukemia is one of the most prominent late effects of exposure to ionising radiation, but is an uncommon complication of exposure to 131I. We report here on two patients who were admitted to our clinic 12 and 17 years after very low-dose radioiodine exposure for thyroid diseases with acute myeloid leukaemia and follicular lymphoma, respectively.

Case reports

Case 1: A 55-years old female presented at our Division with pancytopenia in January 2007, 12 years after 90 mCi radioiodine treatment for Graves’ disease. Molecular biology studies showed no AML1-ETO, BCR/ABL p190(e1a2), BCR/ABL p210 (b3a2), BCR/ABL p210/b2a2), and TEL/AML1, gene translocations, and immunohistochemistry for nucleophosmin excluded mutations in this gene. Cytogenetics showed a normal female karyotype with isochromosome 7q.

Immunophenotyping was negative (< 5%) for sCD3, CD3, CD4, CD7, CD10, CD16, CD19, CD20, CD22, CD41a, CD56, CD61, CD117, MPO and TdT, but positive for CD14 (81%), CD15 (81%), CD33 (93%), CD34 (9%), CD11b (87%), and HLA-DR (51%) in the blast gate. The patient was diagnosed with acute myeloid leukaemia (FAB subtype M4) and underwent conventional chemotherapy with idarubicin and cytarabine, achieving complete remission without complications. She was then consolidated with etoposide, idarubicin and cytarabine, still maintaining complete remission and was scheduled for an allogeneic stem cell transplantation, which is pending at the time of our report.

Case 2: A 56-years old female presented with an enlarged righ axillary lymph node in November 2004 : a lymph node biopsy showed follicular lymphoma grade I, stage IV (lymphomatous B-cell infiltration detected in bone marrow smear and trephine biopsy and clonal IGHV and BCL2-IGHV gene rearrangements in bone marrow blood). She had been diagnosed 16 years before with papillary thyroid carcinoma and treated with partial thyroidectomy and immediate adjuvant radioiodine (30 mCi). Two years later she had been consolidated with an additional dose of radioiodine (130 mCi). Apart from therapeutic radioiodine, she had also performed 4 whole-body scintigraphies with 131I, for a total dose of 11 mCi (cumulative dose: 171 mCi). She was treated with R-CHOP and achieved partial remission, which persisted after salvage chemotherapy according to the R-DHAP scheme. On partial remission, she was treated with 4 administrations of rituximab while awaiting high-dose chemotherapy (according to the BEAM protocol) and autologous hematopoietic stem cell support.

Discussion

Myelodysplastic syndrome has been previously reported in a 67-years old woman after 820 mCi of 131I for thyroid cancer (and who ultimately evolved to leukaemia)1 and in another patient who also received external beam radiation therapy.2

Leukemia after treatment for thyrotoxicosis has been previously reported,3–5 even if the 36-yr follow-up of 116 patients under the age of 20 yr with Graves' disease who were treated with radioiodine between 1953 and 1973 did not disclose any leukaemia case.6

Leukemia as a second malignancy after treatment of thyroid cancer is rare and was first reported in 1955.8 Most cases in the literature are represented by acute leukemia8–13 and have occurred after cumulative doses higher than 800 mCi,14 with a case of M6 AML occurring after as long as 8 years.7 Despite this, 2 cases of acute myeloid leukaemia (AML) (one M2 and the other M3) have been reported after single dosage of only 150 mCi,9 and a third case after 2 doses of 150 mCi.15 The risk associated with microdoses has also been suggested by Laurenti et al, who reported a 45-years old female who developed M2 AML 14 months after a single dose of just 23 mCi.7 At least 2 cases of acute promyelocytic leukaemia (AML M3, APL) have been reported : Kolade et al reported a 51-year-old woman who developed APL within 27 months of completing a cumulative dose of radioiodine of 22.1 mCi,16 while Roldan et al reported APL after single dosage of only 150 mCi.9

Chronic leukaemia has also been reported after 131I treatment. At least 10 cases of chronic myeloid leukemia (CML) have been reported after radioiodine treatment of thyroid cancer with a total dose less than 150 mCi,17–20 one 13 years after a cumulative dose of 670 mCi18 and another 14 years after.19

A general recommendation is that the bone marrow should not receive a total dose which exceeds 1000 mCi, and there should be an interval of at least one year between doses.15 Almost all cases reported in the literature occurred after a total dose of more than 800 mCi and with an interval between doses of 2 and 6 months.15,22 Total quantities up to 1 Ci or more may be used, with a limiting factor being a 200 rad acute exposure to the bone marrow.21 131I at any dose could cause sublethal damage to the bone marrow, but individual susceptibility cannot be excluded in patients developing leukemia after 131I treatment.

Since 131I was introduced for hyperthyroidism, no apparent increase in the incidence of leukaemia has been detected,14,23 although an increased (but not statistically significant) risk was observed for both chronic lymphocytic leukemia (CLL) and non-CLL in two large retrospective studies from Sweden;10,14,24 leukemia has also been reported in rare cases as a complication of 131I treatment for metastatic thyroid cancer, although epidemiological analyses show conflicting results.15,22,25 As a matter of fact, the incidence of leukemia after 131I treatment for thyroid cancer is estimated at around 2% in large series,2,12,13 while the incidence of leukemia after 131I treatment for hyperthyroidism, which is a relatively benign condition, is still a matter of debate.14,24

On the other hand, lymphoma is an extremely rare occurrence after 131I treatment. Wiseman et al reported two cases of lymphoma of the parotid gland 10 and 3 years after 675 mCi and 350 mCi radioiodine therapy for thyroid carcinoma, respectively.26

131I is widely used in the treatment of hyperthyroidism and for remnant ablation in patients with differentiated thyroid cancers,27 and it is considered an efficacious and safe approach, although recently some authors prudentially restrict its use to older patients after surgery or medical failure. In conclusion, since the benefits of radioactive iodine therapy in the treatment of hyperthyroidism and thyroid cancer are proven and the use of 131I appears to be increasing for nonmalignant thyroid diseases,6 a strict hematological follow-up of patients submitted to 131I is warranted in order to accurately detect the incidence of leukemias and lymphomas. Although the development of these malignancies can be due to aging or other causes rather than exposure to 131I treatment, its role could have been underestimated. Radioprotectants such as amifostine could eventually be used to reduce extrathyroid toxicity.

  • Copyright© Ferrata Storti Foundation

References

  1. ↵
    1. Yoosufani Z,
    2. Slavin JJ,
    3. Hellman R,
    4. Sethi S,
    5. Spencer R
    (1987) Preleukemia following large dose radioiodide therapy for metastatic thyroid carcinoma. J Nucl Med 28:1348–50.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Brown A,
    2. Greening W,
    3. McGready V
    (1984) Radioiodine treatment of metastatic thyroid carcinoma; the Royal Marsden Hospital experience. Br J Radial 57:323–7.
    OpenUrl
  3. ↵
    1. Thomson J
    (1963) Acute leukemia following administration of radioiodine for thyrotoxicosis. Lancet 186:978–9.
    OpenUrlCrossRef
    1. Vetter H,
    2. Hofer R
    (1959) Acute leukaemia following radioiodine therapy of thyrotoxicosis. Br J Radiol 32:263–4.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Ghadban W,
    2. Zirie M,
    3. Al-Khateeb DJAA,
    4. Mobayedh H,
    5. El-Aloosy A
    (2003) Radioiodine treatment of hyperthyroidism. Success rate and influence of thyrostatic medication. Saudi Med J 24:347–51.
    OpenUrlPubMedWeb of Science
  5. ↵
    1. Read CJ,
    2. Tansey M,
    3. Menda Y
    (2004) A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves' patients. J Clin Endocrinol Metab 89:4229–33.
    OpenUrlCrossRefPubMedWeb of Science
  6. ↵
    1. Laurenti L,
    2. Salutari P,
    3. Sica S,
    4. et al.
    (1998) Acute myeloid leukemia after iodine-131 treatment for thyroid disorders. Ann Hematol 76:271–2.
    OpenUrlCrossRefPubMedWeb of Science
  7. ↵
    1. Blom P,
    2. Querido A,
    3. Leeksma C
    (1955) Acute leukaemia following x-ray and radioiodine treatment of thyroid carcinoma. Br J Radiol 28:165–6.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    1. Roldan Schilling V,
    2. Fernandez Abellan P,
    3. Dominguez Escribano J,
    4. Rivas Gonzalez C,
    5. Mut Barbera E,
    6. Calatayud Cendra R
    (1998) Acute leukemias after treatment with radioiodine for thyroid cancer. Haematologica 83:767–8.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Hall P,
    2. Boice J,
    3. Berg G
    (1992) Leukaemia after iodine-131 exposure. Lancet 340:1–4.
    OpenUrlPubMedWeb of Science
    1. Advani S,
    2. Hege U
    (1992) Leukemia after 131I treatment of thyroid cancer--comments on the article 'Second cancer following chemotherapy and radiotherapy--an epidemiological perspective' by J. Kaldor. Acta Oncol 31:65.
    OpenUrlPubMedWeb of Science
  10. ↵
    1. Brincker H,
    2. Hansen H,
    3. Anderson A
    (1973) Induction of leukemia by I-131 treatment of thyroid carcinoma. Br J Cancer 28:232–7.
    OpenUrlCrossRefPubMedWeb of Science
  11. ↵
    1. Pochin E
    (1967) Prospects for the treatment of thyroid carcinoma with radioiodide. Clin Radial 18:113–5.
    OpenUrlCrossRef
  12. ↵
    1. Hall P,
    2. Holm L
    (1992) Cancer in iodine-131 exposed patients. J Endocrinol Invest 18:147–9.
    OpenUrl
  13. ↵
    1. Bitton R,
    2. Sachmechi I,
    3. Benegalrao Y,
    4. Schneider B
    (1993) Leukemia after a small dose of radioiodine for metastatic thyroid cancer. J Clin Endocrinol Metab 77:1423–6.
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    1. Kolade V,
    2. Bosinski T,
    3. Ruffy E
    (2005) Acute promyelocytic leukemia after iodine-131 therapy for Graves' disease. Pharmacotherapy 25:1017–20.
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    1. Shimon I,
    2. Kneller A,
    3. Olchovsky D
    (1995) Chronic myeloid leukaemia following 131I treatment for thyroid carcinoma: a report of two cases and review of the literature. Clin Endocrinol (Oxf) 43:651–4.
    OpenUrlPubMed
  16. ↵
    1. Wang K,
    2. Lin L,
    3. Chen P,
    4. Lin H
    (2005) Chronic myeloid leukemia after treatment with 131 for thyroid carcinoma. J Chin Med Assoc 68:230–3.
    OpenUrlPubMed
  17. ↵
    1. Pavithran K,
    2. Doval D
    (2005) Chronic myeloid leukemia in a man with papillary carcinoma of the thyroid treated with radioactive iodine. Am J Clin Oncol 28:216.
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    1. Walgraeve D,
    2. Verhoef G,
    3. Stul M,
    4. et al.
    (1991) Chronic myelogenous leukemia after treatment with 131I for thyroid carcinoma. Report of a case and review of the literature. Cancer Genet Cytogenet 55:217–24.
    OpenUrlCrossRefPubMedWeb of Science
    1. Boice JD Jr.,
    2. Fraumeni JF Jr.
    1. Holm L
    (1984) in Radiation carcinogenesis: epidemiology and biological significance, Malignant disease following iodine-131 therapy in Sweden, eds Boice JD Jr., Fraumeni JF Jr. (Raven Press, New York), pp 263–71.
  19. ↵
    1. De Vathaire F,
    2. Schlumberger M,
    3. Delisle M
    (1997) Leukaemias and cancers following iodine-131 administration for thyroid cancer. Br J Cancer 75:734–9.
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    1. Hoffman D,
    2. McConahey W,
    3. Fraumeni J,
    4. Kurland L
    (1982) Cancer incidence following treatment of hyperthyroidism. Int J Epidemiol 11:218–24.
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Holm L,
    2. Hall P,
    3. Wiklund K,
    4. et al.
    (1995) Cancer risk after iodine-131 therapy for hyperthyroidism, 86:1026–7.
  22. ↵
    1. Edmonds C,
    2. Smith T
    (1986) The long-term hazards of the treatment of thyroid cancer with radioiodine. Br J Radiol 59:45–51.
    OpenUrlAbstract/FREE Full Text
  23. ↵
    1. Wiseman J,
    2. Hales I,
    3. Joasoo A
    (1982) Two cases of lymphoma of the parotid gland following ablative radioiodine therapy for thyroid carcinoma. Clin Endocrinol (Oxf) 17:85–9.
    OpenUrlPubMed
  24. ↵
    1. Hackshaw A,
    2. Harmer CMU,
    3. Haq M,
    4. Franklyn J
    (2007) 131I activity for remnant ablation in patients with differentiated thyroid cancer: A systematic review. J Clin Endocrinol Metab 92:28–38.
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top

Vol 92 Issue 9

Haematologica: 92 (9)
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
Email

Thank you for your interest in spreading the word about Haematologica.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Acute myeloid leukemia and follicular lymphoma after very low dose radioiodine therapy for thyroid diseases
(Your Name) has forwarded a page to you from Haematologica
(Your Name) thought you would like to see this page from the Haematologica web site.
Print
Citation Tools
Acute myeloid leukemia and follicular lymphoma after very low dose radioiodine therapy for thyroid diseases
Daniele Focosi, Sara Galimberti, Mario Petrini
Haematologica Sep 2007, 92 (9) e96-e97; DOI: 10.3324/haematol.11981

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Daniele Focosi, Sara Galimberti, Mario Petrini
Haematologica Sep 2007, 92 (9) e96-e97; DOI: 10.3324/haematol.11981
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Request Permissions
  • Tweet Widget
  • Facebook Like
  • Alert me when this article is cited
  • Alert me if a correction is posted

Jump To

  • Article
    • Introduction
    • Case reports
    • Discussion
    • References
  • Info & Metrics
  • PDF

More in this TOC Section

  • Molecular remissions are observed in chronic adult T-cell leukemia/lymphoma in patients treated with mogamulizumab
  • The non-erythroid myeloblast count rule in myelodysplastic syndromes: fruitful or futile?
  • Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses
Show more Online Only Articles

Related Articles

Cited By...

What about you?
Tell us your interests and get all the new contents of Haematologica in advance

 

 

Navigate

  • Home
  • Current issue
  • Ahead of print
  • Archive
  • Info for
    • Authors
    • Reviewers
    • Advertisers
    • Subscribers
  • About us
    • About Haematologica
    • Editorial Board
    • Our policies

For Authors

  • Author guidelines
  • Submit Manuscript
  • Track Manuscript

For Reviewers

  • Reviewer Guidelines
  • Access Your Profile
  • Access Your Tasks
  • 2014 reviewers

For Advertisers

  • Information For Advertising

Education

  • Review Articles
  • Guideline Articles

More

  • Rights & Permissions
  • Advertising
  • Alerts
  • Feedback
  • Contact
  • App

Copyright © 2019 by the Ferrata Storti Foundation

ISSN 0390-6078 print

ISSN 1592-8721 online